Abstract
The COVID-19 pandemic has crudely demonstrated the value of massive and rapid diagnostics. By the first week of April, more than 900,000 positive cases of COVID-19 have been reported worldwide, although this number could be greatly underestimated. In the case of an epidemic emergency, the first line of response should be based on commercially available and validated resources. Here, we demonstrate the combined use of the miniPCR®, a commercial compact and portable PCR device recently available on the market, and a commercial well-plate reader as a diagnostic system for detecting SARS-CoV-2 nucleic acids. We used the miniPCR to detect and amplify SARS-CoV-2 DNA sequences using the sets of initiators recommended by the World Health Organization for targeting three different regions that encode for the N protein. Prior to amplification, samples were combined with a DNA intercalating reagent (i.e., EvaGreen® Dye). Sample fluorescence after amplification was then read using a commercial 96-well plate reader. This straightforward method allows the detection and amplification of SARS-CoV-2 nucleic acids in the range of ∼625 to 2×105 DNA copies. The accuracy and simplicity of this diagnostics strategy may provide a cost-efficient and reliable alternative for COVID-19 pandemic testing, particularly in underdeveloped regions where RT-QPCR instrument availability may be limited. The portability, ease of use, and reproducibility of the miniPCR® makes it a reliable alternative for deployment in point-of-care SARS-CoV-2 detection efforts during pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors aknowledge the funding provided by the Federico Baur Endowed Chair in Nanotechnology (0020240I03). EGG acknowledges funding from a doctoral scholarship provided by CONACyT (Consejo Nacional de Ciencia y Tecnología, México). GTdS and MMA acknowledge the institutional funding received from Tecnológico de Monterrey (Grant 002EICIS01). MMA, GTdS, SOMC and IMLM acknowledge funding provided by CONACyT (Consejo Nacional de Ciencia y Tecnología, México) through grants (SNI 26048, SNI 256730, SNI 31803).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The set of raw data used to produce the graphs reported here is all presented within this manuscript or provided as supplementary material
